MedTrace Logo

Dupilumab in Chinese Adult Participants With CRSwNP

NCT05878093 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-09-25

Study results available
· View outcomes & findings →

Summary

This is a parallel group, Phase 3, 2-arm study for treatment. The purpose of this study is to evaluate dupilumab subcutaneous (SC) injections compared to placebo in Chinese adult participants with CRSwNP, on a background therapy with intranasal corticosteroids (budesonide nasal spray).

Study details include:

* The study duration will be up to 40 weeks.
* The treatment duration will be up to 24 weeks.
* The number of visits will be 7.

Conditions

Interventions

DRUG

Dupilumab

solution for subcutaneous injection

DRUG

Placebo

solution for subcutaneous injection

DRUG

Budesonide

nasal spray (suspension)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-16
Primary Completion
2024-09-06
Completion
2024-11-28
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05878093 on ClinicalTrials.gov